Salomon M. Stemmer

Research interests

Publications

• Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

  New England Journal of Medicine · 2022 · 10.1056/nejmoa2114663

• Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

  The Breast · 2021 · 10.1016/j.breast.2021.08.016

• Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

  JAMA Oncology · 2021 · 10.1001/jamaoncol.2021.2155

• Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.05.001

• Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

  Journal of Clinical Oncology · 2020 · 10.1200/jco.20.03007

• BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0880-x

• Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals

  PLoS Genetics · 2019 · 10.1371/journal.pgen.1008181

• Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy155

• A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

  Oncotarget · 2017 · 10.18632/oncotarget.17742

• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6

• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1609709

• Cryopreservation ofin vitromatured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy

  Human Reproduction · 2016 · https://doi.org/10.1093/humrep/dew007

• Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

  Gynecologic Oncology · 2015 · 10.1016/j.ygyno.2015.12.020

• Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv597

• The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy

  Cell · 2014 · 10.1016/j.cell.2014.05.045

• Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2014.56.2728

• Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.2408

• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

  Annals of Oncology · 2011 · https://doi.org/10.1093/annonc/mdr435

• Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib

  Dermatologic Therapy · 2011 · https://doi.org/10.1111/j.1529-8019.2011.01431.x

• Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials

  JNCI Journal of the National Cancer Institute · 2010 · 10.1093/jnci/djq409

• Doxorubicin-induced ovarian toxicity

  Reproductive Biology and Endocrinology · 2010 · 10.1186/1477-7827-8-20

• Interventions for Alleviating Cancer-Related Dyspnea: A Systematic Review

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.15.5796

• Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.09.0886

• White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy.

  PubMed · 1998

• Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.

  Journal of Clinical Oncology · 1994 · 10.1200/jco.1994.12.1.28

Current projects

No projects listed.